brand-logo

Accelagen Exhibiting at Ausbiotech + Invest 2020!

Accelagen Exhibiting at Ausbiotech + Invest 2020!

Accelagen is proud to announce it will be exhibiting at the virtual Ausbiotech + Invest 2020 Conference occurring on 28 – 30 October. Ausbiotech will be delivering a brand-new live and on-demand digital platform! Accelagen is excited to participate in this fresh and dynamic virtual event.

Despite the COVID-19 pandemic across the world, we have been continuing our work to help clients navigate successful development pathways. With over 10 years of local and international client partnerships, Accelagen is equally committed in helping clients begin new therapeutic programs.

The virtual Ausbiotech + Invest 2020 Conference is a fantastic opportunity to connect with one another. The Accelagen team hopes you may join us at the event to learn more about our services and programs.

You might also like...​

You might also like...​

New Appointment Post – Sahar Bassal

New Appointment Post – Sahar Bassal One thing that we never lose sight of at Accelagen is that, on the end of every product, every trial, every protocol, every drug — is a patient. And it is our responsibility, and our privilege, to help our innovative global clients to translate ground-breaking science into meaningful gains […]

Read More
Accelagen team
New Appointment Post – Dominique

New Appointment Post – Dominique Wrangling kids down at Auskick and wrangling the many moving parts of a clinical trial is all in a day’s work for Accelagen’s new Clinical Project Manager, Dominique Holden. Bringing over 10 years’ experience in clinical research and an exemplary approach to trial management, Dominique was drawn to Accelagen’s reputation […]

Read More
Hands operating syringe
Accelagen accelerates time to market for European clients: Potentially best-in-class study for Treatment of BKV Infection sees exciting results

Accelagen accelerates time to market for European clients: Potentially best-in-class study for Treatment of BKV Infection sees exciting results Local CRO, Accelagen, attracts innovative European drug and antibody developers to trial in Australian market Engaged by world-renowned European clients and collaborators, Memo Therapeutics AG (“MTx”) based in Switzerland, and Vakzine Projekt Management GmbH (VPM) based […]

Read More